




TOXICOLOGICAL STUDIES OF POLY (ANHYDRIDE) NANOPARTICLES FOR ORAL DRUG DELIVERY

PATRICIA OJER OJER

Department of Pharmacy and Pharmaceutical Technology¹
&
Department of Nutrition and Food Sciences , Physiology and Toxicology²
University of Navarra

Dr. Juan Manuel Irache¹

Dra. Adela López de Cerain²






Solid particles colloidally dispersed sized between 1 and 1000 nm


NANOSPHERES

(Drug uniformly dispersed)



NANOCAPSULES

(Encapsulated drug)



APPLICATIONS

Drug delivery:

↓ dose administration

Minimize drug degradation


↑ efficacy

ORAL DRUG DELIVERY



GANTREZ® AN 119

- Poly (methyl vinyl ether - co - maleic anhydride)
- Synthetic and biocompatible
- Low cost



PHYSICO-CHEMICAL PROPERTIES OF GANTREZ® AN 119

- Specific viscosity (1% MEK): 0.1 - 0.5
- T_g: 152 °C
- Viscosity of 5% w/w solution at 25°C: 15 mPas



PHARMACEUTICAL APPLICATIONS

- **Dental adhesives**

high quality bioadhesive performance

- **Controlled-release coatings, enteric coatings and ostomy adhesives**


Excellent film-forming properties

- **Transdermal patches, toothpastes, mouthwashes and transdermal gels**


Thickeners, complexing agents and hydrophilic colloids

- **Specific bioadhesive ligand-nanoparticle conjugates for oral drug delivery**

Fabrication of nanoparticles for oral drug delivery: Spanish patent, Arbos, P. et al, 2002




Gantrez[®] AN 119 polymer




Gantrez[®] AN 119 x12500

Solvent Displacement Method



Gantrez[®] AN 119 Nanoparticles



Gantrez[®] AN 119 Nanoparticles x 5000




- Preparation of different types of nanoparticles:
 - ✓ Conventional nanoparticles (NP)
 - ✓ Pegylated nanoparticles (PEG-NP)
 - ✓ Cyclodextrin nanoparticles (HP β CD-NP)
- Physico Chemical characterization of nanoparticles prepared:
 - ✓ Size
 - ✓ Surface charge
 - ✓ Shape
 - ✓ Stability
- Evaluate the cytotoxicity of Gantrez[®] AN poly (anhydride) nanoparticles by MTS assay using the Hep G2 cell line




- Conventional nanoparticles (NP)

↑ Bioavailability of the presystemically metabolised drug




- Pegylated nanoparticles (PEG-NP)

↓ interaction of nanoparticles with components of the lumen




- Cyclodextrin nanoparticles (HP β CD-NP)

↑ Loading capacity of lipophilic drugs in the nanoparticles






Fluorescence microscopic visualization



- Poly (anhydride) nanoparticles (NP) displayed a restricted location at the mucosa, mainly on the mucus layer of the ileum, and a low ability to cross this barrier
- Nanoparticles associated to hydroxypropyl- β -CD (HP β CD NP) and pegylated nanoparticles (PEG2000 NP) distributed homogeneously along the ileum mucosa and show high ability to establish bioadhesive interactions.




Solvent Displacement Method






	Size (nm)	Zeta Potential (mV)	$\mu\text{g ligand/mg Np}$
NP	192 ± 2	-56.8 ± 0.5	
HP β CD-NP	168 ± 1	-52.8 ± 0.5	219.3 ± 3.2
PEG 2000-NP	205 ± 1	-57.1 ± 0.7	25.7 ± 0.5
Mean values \pm SD (n=6)			


NP SEM IMAGES



NP



HP β CD-NP



PEG 2000-NP




In cytotoxicity of nanoparticles it is important to :

- **Develop the complete physico-chemical characterization of the nanoparticles**
- **Choose cell cultures sensitive to changes in their environment**
- **Controlling the experimental conditions**



NANOPARTICLES STABILITY


- Measure Turbidity change as a function of time
- 15 mg NP/mL DPBS w/o $\text{Ca}^{++}/\text{Mg}^{++}$
- $t_{1/2} = 50$ minutes






- Cell line: **Hep G2** (Human liver adenocarcinoma)
 - Oral route
 - Sensitive to damage
- Cell viability: **MTS ASSAY**

(“CellTiter 96[®] Aq_{ueous} Non-Radioactive Cell Proliferation Assay”)
- Concentrations tested: **0.0625 – 0.125 – 0.25 – 0.5 - 1 and 2 mg/mL**
- Incubation time: **30 minutes, 3, 24, 48 and 72 hours**



Hep G2 cells

Cultured in 96 well-plates



2×10^4 cs/well

Nanoparticles addition

- (NP)
- (HP β CD-NP)
- (PEG 2000-NP)
- (Gantrez[®] AN polymer)

30 minutes

3 hours

24 hours

48 hours

72 hours

Cell-Nanoparticles
Incubation


% Cell Viability

Measure 96 well-plates at 490 nm



MTS ASSAY



CONTROL




POLY (ANHYDRIDE) GANTREZ® AN 119




For the poly (anhydride) Gantrez® AN, the morphology of the cells could not be observed probably due to the deposition of the polymer on the cells similar to a coating




MTS results: Cell Viability



NP Concentrations



PEG2000 NP Concentrations




HPβCD NP Concentrations

- 30 min, 3 and 24 hours no significant decrease was observed
- 48 and 72 hours a significant cytotoxic effect was observed at the highest concentrations tested (1, 2 mg/mL)



* and † :Results were significant at 0.05 level (Kruskal Wallis-U-Mann Whitney)




Hep G2 Images



30 min, 3 and 24 hours



48 and 72 hours



Incubation times of 30 minutes, 3 and 24 hours did not affect the morphology nor the growth of Hep G2 cells.

On the contrary, at 48 and 72 hours, at the highest concentrations tested morphological changes and decrease in cell viability were observed.



pH VALUES

INCUBATION TIMES	Poly (anhydride) Gantrez® AN 119	NP	HPβCD NP	PEG ₂₀₀₀ NP	DME M
30 min	6	6.5	7	7	7
3 h	6	6	6	6.5	7
24 h	6	6	6	6	6.5
48 h	6-7.5	7.5	7.5	7.5	8
72 h	6-7	7.5	7.5	7.5	8

No pH changes were appreciated in culture media as a consequence of the nanoparticles and polymer addition at the different incubation times tested



- The nanoparticles were prepared by two methods. The poly(anhydride) nanoparticles displayed a size of approximately 190 nm, a negative surface charge and a spherical shape with a homogeneous size distribution.
- The cytotoxicity studies demonstrated that the poly(anhydride) nanoparticles did not show any toxic effect in Hep G2 cells at 30 minutes, 3 and 24 hours.
- In contrast, at 48 and 72 hours significant cytotoxic effects were observed for 1 and 2 mg/mL nanoparticles concentrations.



- **Departamento de Educación del Gobierno de Navarra**
- **Proyecto “Nanotecnologías y Medicamentos”**



(Fundación Caja Navarra)



TOXICOLOGICAL STUDIES OF POLY (ANHYDRIDE) NANOPARTICLES FOR ORAL DRUG DELIVERY

PATRICIA OJER OJER

Department of Pharmacy and Pharmaceutical Technology¹
&

Department of Nutrition and Food Sciences , Physiology and Toxicology²

University of Navarra

Dr. Juan Manuel Irache¹

Dr. Adela López de Cerain²